scispace - formally typeset
H

Hideyuki Yanai

Researcher at University of Tokyo

Publications -  66
Citations -  13861

Hideyuki Yanai is an academic researcher from University of Tokyo. The author has contributed to research in topics: Immune system & Innate immune system. The author has an hindex of 36, co-authored 61 publications receiving 12637 citations.

Papers
More filters
Journal ArticleDOI

IRF-7 is the master regulator of type-I interferon-dependent immune responses

TL;DR: It is shown that mice deficient in the Irf7 gene are more vulnerable than Myd88-/- mice to viral infection, and this correlates with a marked decrease in serum IFN levels, indicating the importance of the IRF-7-dependent induction of systemic IFN responses for innate antiviral immunity.
Journal ArticleDOI

DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response

TL;DR: The artificial expression of otherwise IFN-inducible DAI (DLM-1/ZBP1) in mouse fibroblasts selectively enhances the DNA-mediated induction of type I IFN and other genes involved in innate immunity, and may offer new insight into the signalling mechanisms underlying DNA-associated antimicrobial immunity and autoimmune disorders.
Journal ArticleDOI

The IRF Family Transcription Factors in Immunity and Oncogenesis

TL;DR: The role of several IRF family members in the regulation of the cell cycle and apoptosis has important implications for understanding susceptibility to and progression of several cancers.
Journal ArticleDOI

Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors

TL;DR: The transcription factor IRF-5 is identified as a new, principal downstream regulator of the TLR–MyD88 signalling pathway and a potential target of therapeutic intervention to control harmful immune responses.
Journal ArticleDOI

Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction.

TL;DR: Insight is offered into the regulation of TLR9 signalling in space, potentially suggesting a new avenue for therapeutic intervention in response toTLR9 activation.